Literature DB >> 26844676

Xp11 neoplasm with melanocytic differentiation of the prostate harbouring the novel NONO-TFE3 gene fusion: report of a unique case expanding the gene fusion spectrum.

Xiao-Tong Wang1,2, Qiu-Yuan Xia1, Hao Ni1,2, Zi-Yu Wang3, Sheng-Bing Ye1, Rui Li1, Xuan Wang1, Jing-Huan Lv1, Shan-Shan Shi1, Heng-Hui Ma1, Zhen-Feng Lu1, Qin Shen1, Xiao-Jun Zhou1, Qiu Rao1,2.   

Abstract

Recently, an increasing number of TFE3 rearrangement-associated tumours have been reported, such as TFE3 rearrangement-associated perivascular epithelioid cell tumours (PEComas), melanotic Xp11 translocation renal cancers and melanotic Xp11 neoplasms. We have suggested that these tumours belong to a single clinicopathological spectrum. 'Xp11 neoplasm with melanocytic differentiation' or 'melanotic Xp11 neoplasm' have been proposed to designate this unique neoplasm. Herein, we describe the first case of an Xp11 neoplasm with melanocytic differentiation to be described in the prostate, bearing the novel NONO-TFE3 gene fusion. This study both adds to the spectrum regarding melanotic Xp11 neoplasms and expands its gene fusion spectrum. Moreover, we discuss the relationship of these rare tumours to neoplasms such as conventional PEComas, alveolar soft part sarcomas, malignant melanomas, clear cell sarcomas and Xp11 translocation renal cancers.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  NONO; PSF/SFPQ; TFE3; Xp11 translocation; fluorescence in-situ hybridization; gene fusion; melanocytic differentiation; perivascular epithelioid cell tumour; prostate

Mesh:

Substances:

Year:  2016        PMID: 26844676     DOI: 10.1111/his.12949

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

1.  Novel recurrent PHF1-TFE3 fusions in ossifying fibromyxoid tumors.

Authors:  Albert J H Suurmeijer; Wangzhao Song; Yun-Shao Sung; Lei Zhang; David Swanson; Christopher D M Fletcher; Brendan C Dickson; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2019-04-17       Impact factor: 5.006

2.  Endometrial polyp-like perivascular epithelioid cell neoplasm associated with TFE3 translocation: report of one case.

Authors:  Yanting Hu; Lixia Wang; Hongqi Shi; Bin Hu
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

3.  TFE3-Expressing Perivascular Epithelioid Cell Neoplasm (PEComa) of the Sella Turcica.

Authors:  Martin D Hyrcza; Daniel A Winer; Mary Shago; Karolyn Au; Gelareh Zadeh; Sylvia L Asa; Ozgur Mete
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

4.  Nuclear translocation of ASPL-TFE3 fusion protein creates favorable metabolism by mediating autophagy in translocation renal cell carcinoma.

Authors:  Ru Fang; Xiaotong Wang; Qiuyuan Xia; Ming Zhao; Hao Zhang; Xuan Wang; Shengbing Ye; Kai Cheng; Yan Liang; Yang Cheng; Yayun Gu; Qiu Rao
Journal:  Oncogene       Date:  2021-04-12       Impact factor: 9.867

5.  Melanotic Xp11-associated tumor of the sigmoid colon: A case report.

Authors:  Gang Wang; Gang-Gang Li; Sheng-Mao Zhu; Bao-Jia Cai; Peng-Jie Yu; Cheng-Wu Zhang
Journal:  World J Clin Cases       Date:  2019-03-06       Impact factor: 1.337

Review 6.  Complexity of PEComas : Diagnostic approach, molecular background, clinical management.

Authors:  K Utpatel; D F Calvisi; G Köhler; T Kühnel; A Niesel; N Verloh; M Vogelhuber; R Neu; N Hosten; H-U Schildhaus; W Dietmaier; M Evert
Journal:  Pathologe       Date:  2020-06       Impact factor: 1.011

7.  The suitability of NONO-TFE3 dual-fusion FISH assay as a diagnostic tool for NONO-TFE3 renal cell carcinoma.

Authors:  Ning Liu; Wei Guo; Qiancheng Shi; Wenyuan Zhuang; Xiaohong Pu; Shaoyu Chen; Feng Qu; Linfeng Xu; Xiaozhi Zhao; Xiaogong Li; Gutian Zhang; Hongqian Guo; Weidong Gan; Dongmei Li
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

Review 8.  Overview of research on fusion genes in prostate cancer.

Authors:  Chunjiao Song; Huan Chen
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.